安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
- Targeting ALK Rearrangements in NSCLC: Current State of the Art
Currently, six ALK-target agents have been approved to treat advanced ALK+ NSCLC, including crizotinib, alectinib, ceritinib, ensartinib, brigatinib, and lorlatinib These targeted agents induce durable responses and improve survival outcomes Treatment with ALK inhibitors is recognized as the standard of care for advanced ALK+ NSCLC
- ALK+ NSCLC Treatment Guidelines
Use of ALK TKIs is effective for treatment of patients with ALK+ NSCLC and CNS involvement, and evidence supports alectinib, brigatinib or ceritinib in this setting as first-line therapy
- FDA Approves Alectinib for ALK-Positive Lung Cancer
Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
- FDA approves alectinib as adjuvant treatment for ALK-positive . . .
On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc ) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK
- Neladalkib Shows Durable Responses in Heavily Pretreated ALK . . .
Key Takeaways Neladalkib shows a 31% ORR in advanced ALK-positive NSCLC, with durable responses in 64% and 53% at 12 and 18 months, respectively The drug effectively penetrates the blood-brain barrier, showing significant intracranial activity, especially in lorlatinib-naïve patients and those with the ALK G1202R mutation
- Neladalkib Demonstrates Promising Responses in ALK+ NSCLC
Neladalkib shows promising efficacy in advanced ALK+ NSCLC, offering durable responses and manageable safety, potentially transforming treatment options
- ALK Alterations and Treatment Options for ALK+ NSCLC
Panelists review the discovery of ALK gene fusions and how they have reshaped the treatment landscape for a distinct subset of lung cancer patients They describe how these rearrangements activate
|
|
|